Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With Integration of Biovail Nearly Completed, Valeant Looks For More Deals In 2011

This article was originally published in The Pink Sheet Daily

Executive Summary

Valeant's price-conscious, opportunistic approach to business development and relentless pace of activity has enabled it to quadruple sales in three years and grow its top-line 7% in 2010.

You may also be interested in...

The Quintessential Specialty Pharma, Valeant Embodies PE Tenets

Even as private equity firms reach into specialty pharma niche opportunities for deals, specialty pharma companies are evolving, as well. Valeant Pharmaceuticals is a very visible example of one kind of specialty pharma model, which is based as much upon sophisticated financial engineering as product growth.

Back In Biotech, Waksal's Kadmon Emerges From Stealth Mode To Focus on Hep C

Deal with Valeant brings development and commercialization rights to ribavirin analog that could have better safety profile for anemia.

Tax Benefits Highlight Announced Merger Of Valeant And Biovail

A deal that would combine two smaller specialty pharmas into one will result in a company with four main business areas.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts